Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2013

Open Access 01-12-2013 | Research

FGFR3 has tumor suppressor properties in cells with epithelial phenotype

Authors: Marie Lafitte, Isabelle Moranvillier, Stéphane Garcia, Evelyne Peuchant, Juan Iovanna, Benoit Rousseau, Pierre Dubus, Véronique Guyonnet-Dupérat, Geneviève Belleannée, Jeanne Ramos, Aurélie Bedel, Hubert de Verneuil, François Moreau-Gaudry, Sandrine Dabernat

Published in: Molecular Cancer | Issue 1/2013

Login to get access

Abstract

Background

Due to frequent mutations in certain cancers, FGFR3 gene is considered as an oncogene. However, in some normal tissues, FGFR3 can limit cell growth and promote cell differentiation. Thus, FGFR3 action appears paradoxical.

Results

FGFR3 expression was forced in pancreatic cell lines. The receptor exerted dual effects: it suppressed tumor growth in pancreatic epithelial-like cells and had oncogenic properties in pancreatic mesenchymal-like cells. Distinct exclusive pathways were activated, STATs in epithelial-like cells and MAP Kinases in mesenchymal-like cells. Both FGFR3 splice variants had similar effects and used the same intracellular signaling. In human pancreatic carcinoma tissues, levels of FGFR3 dropped in tumors.

Conclusion

In tumors from epithelial origin, FGFR3 signal can limit tumor growth, explaining why the 4p16.3 locus bearing FGFR3 is frequently lost and why activating mutations of FGFR3 in benign or low grade tumors of epithelial origin are associated with good prognosis. The new hypothesis that FGFR3 can harbor both tumor suppressive and oncogenic properties is crucial in the context of targeted therapies involving specific tyrosine kinase inhibitors (TKIs). TKIs against FGFR3 might result in adverse effects if used in the wrong cell context.
Appendix
Available only for authorised users
Literature
1.
Turner N, Grose R: Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010, 10: 116-129. 10.1038/nrc2780CrossRefPubMed
2.
L’Hote CG, Knowles MA: Cell responses to FGFR3 signalling: growth, differentiation and apoptosis. Exp Cell Res. 2005, 304: 417-431. 10.1016/j.yexcr.2004.11.012CrossRefPubMed
3.
Colvin JS, Bohne BA, Harding GW, McEwen DG, Ornitz DM: Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nat Genet. 1996, 12: 390-397. 10.1038/ng0496-390CrossRefPubMed
4.
Li C, Chen L, Iwata T, Kitagawa M, Fu XY, Deng CX: A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum Mol Genet. 1999, 8: 35-44. 10.1093/hmg/8.1.35CrossRefPubMed
5.
Arnaud-Dabernat S, Kritzik M, Kayali AG, Zhang YQ, Liu G, Ungles C, Sarvetnick N: FGFR3 is a negative regulator of the expansion of pancreatic epithelial cells. Diabetes. 2007, 56: 96-106. 10.2337/db05-1073CrossRefPubMed
6.
Arnaud-Dabernat S, Yadav D, Sarvetnick N: FGFR3 contributes to intestinal crypt cell growth arrest. J Cell Physiol. 2008, 216: 261-268. 10.1002/jcp.21401CrossRefPubMed
7.
Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999, 23: 18-20.PubMed
8.
Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Amoros A, Tardon A, Carrato A, Serra C, Malats N, Real FX: Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol. 2006, 24: 3664-3671. 10.1200/JCO.2005.05.1771CrossRefPubMed
9.
Hernandez S, Toll A, Baselga E, Ribe A, Azua-Romeo J, Pujol RM, Real FX: Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors. J Invest Dermatol. 2007, 127: 1664-1666.PubMed
10.
Jang JH, Shin KH, Park YJ, Lee RJ, McKeehan WL, Park JG: Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. Cancer Res. 2000, 60: 4049-4052.PubMed
11.
Sonvilla G, Allerstorfer S, Heinzle C, Stattner S, Karner J, Klimpfinger M, Wrba F, Fischer H, Gauglhofer C, Spiegl-Kreinecker S: Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration. Br J Cancer. 2010, 102: 1145-1156. 10.1038/sj.bjc.6605596PubMedCentralCrossRefPubMed
12.
Chesi M, Nardini E, Brents LA, Schrock E, Ried T, Kuehl WM, Bergsagel PL: Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997, 16: 260-264. 10.1038/ng0797-260PubMedCentralCrossRefPubMed
13.
14.
Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996, 271: 15292-15297. 10.1074/jbc.271.25.15292CrossRefPubMed
15.
Efrat S, Fusco-DeMane D, Lemberg H, al Emran O, Wang X: Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene. Proc Natl Acad Sci U S A. 1995, 92: 3576-3580. 10.1073/pnas.92.8.3576PubMedCentralCrossRefPubMed
16.
Plath T, Peters M, Detjen K, Welzel M, von Marschall Z, Radke C, Wiedenmann B, Rosewicz S: Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J Natl Cancer Inst. 2002, 94: 129-142. 10.1093/jnci/94.2.129CrossRefPubMed
17.
Li Z, Zhu YX, Plowright EE, Bergsagel PL, Chesi M, Patterson B, Hawley TS, Hawley RG, Stewart AK: The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells. Blood. 2001, 97: 2413-2419. 10.1182/blood.V97.8.2413CrossRefPubMed
18.
Bernard-Pierrot I, Brams A, Dunois-Larde C, Caillault A, de Medina SGD, Cappellen D, Graff G, Thiery JP, Chopin D, Ricol D, Radvanyi F: Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis. 2006, 27: 740-747.CrossRefPubMed
19.
Hirotsu M, Setoguchi T, Matsunoshita Y, Sasaki H, Nagao H, Gao H, Sugimura K, Komiya S: Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer. 2009, 101: 2030-2037. 10.1038/sj.bjc.6605407PubMedCentralCrossRefPubMed
20.
Ishibe T, Nakayama T, Okamoto T, Aoyama T, Nishijo K, Shibata KR, Shima Y, Nagayama S, Katagiri T, Nakamura Y: Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res. 2005, 11: 2702-2712. 10.1158/1078-0432.CCR-04-2057CrossRefPubMed
21.
Sibley K, Cuthbert-Heavens D, Knowles MA: Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. Oncogene. 2001, 20: 686-691. 10.1038/sj.onc.1204110CrossRefPubMed
22.
Dai H, Holm R, Kristensen GB, Abeler VM, Borresen-Dale AL, Helland A: Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas. Anal Cell Pathol. 2001, 23: 45-49.CrossRefPubMed
23.
Mhawech-Fauceglia P, Cheney RT, Fischer G, Beck A, Herrmann FR: FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer. Eur J Surg Oncol. 2006, 32: 231-237. 10.1016/j.ejso.2005.11.018CrossRefPubMed
24.
Zieger K, Marcussen N, Borre M, Orntoft TF, Dyrskjot L: Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. Int J Cancer. 2009, 125: 2095-2103. 10.1002/ijc.24619CrossRefPubMed
25.
Knowles MA: Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol. 2007, 25: 581-593. 10.1007/s00345-007-0213-4CrossRefPubMed
26.
Roger L, Jullien L, Gire V, Roux P: Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells. J Cell Sci. 2010, 123: 1295-1305. 10.1242/jcs.061002CrossRefPubMed
27.
Hayashida Y, Honda K, Idogawa M, Ino Y, Ono M, Tsuchida A, Aoki T, Hirohashi S, Yamada T: E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res. 2005, 65: 8836-8845. 10.1158/0008-5472.CAN-05-0718CrossRefPubMed
28.
McInroy L, Maatta A: Down-regulation of vimentin expression inhibits carcinoma cell migration and adhesion. Biochem Biophys Res Commun. 2007, 360: 109-114. 10.1016/j.bbrc.2007.06.036CrossRefPubMed
29.
Ronchetti D, Greco A, Compasso S, Colombo G, Dell’Era P, Otsuki T, Lombardi L, Neri A: Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations. Oncogene. 2001, 20: 3553-3562. 10.1038/sj.onc.1204465CrossRefPubMed
30.
Leung HY, Gullick WJ, Lemoine NR: Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer. Int J Cancer. 1994, 59: 667-675. 10.1002/ijc.2910590515CrossRefPubMed
31.
Krejci P, Prochazkova J, Smutny J, Chlebova K, Lin P, Aklian A, Bryja V, Kozubik A, Wilcox WR: FGFR3 signaling induces a reversible senescence phenotype in chondrocytes similar to oncogene-induced premature senescence. Bone. 2010, 47: 102-110. 10.1016/j.bone.2010.03.021PubMedCentralCrossRefPubMed
32.
Hubackova S, Novakova Z, Krejcikova K, Kosar M, Dobrovolna J, Duskova P, Hanzlikova H, Vancurova M, Barath P, Bartek J, Hodny Z: Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling. Cell Cycle. 2010, 9: 3085-3099. 10.4161/cc.9.15.12521CrossRefPubMed
33.
Bellido T, O’Brien CA, Roberson PK, Manolagas SC: Transcriptional activation of the p21(WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem. 1998, 273: 21137-21144. 10.1074/jbc.273.33.21137CrossRefPubMed
34.
Lafitte M, Rousseau B, Moranvillier I, Taillepierre M, Peuchant E, Guyonnet-Duperat V, Dubus P, Bedel A, de Verneuil H, Moreau-Gaudry F, Dabernat S: In vivo gene transfer targeting in pancreatic adenocarcinoma with cell surface antigens. Mol Cancer. 2012, 11: 81- 10.1186/1476-4598-11-81PubMedCentralCrossRefPubMed
Metadata
Title
FGFR3 has tumor suppressor properties in cells with epithelial phenotype
Authors
Marie Lafitte
Isabelle Moranvillier
Stéphane Garcia
Evelyne Peuchant
Juan Iovanna
Benoit Rousseau
Pierre Dubus
Véronique Guyonnet-Dupérat
Geneviève Belleannée
Jeanne Ramos
Aurélie Bedel
Hubert de Verneuil
François Moreau-Gaudry
Sandrine Dabernat
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2013
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-12-83

Other articles of this Issue 1/2013

Molecular Cancer 1/2013 Go to the issue

Research

Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer

Research

MutS homologue hMSH4: interaction with eIF3f and a role in NHEJ-mediated DSB repair

Research

Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres

Research

Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer

Review

Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds

Research

1H-NMR based metabonomic profiling of human esophageal cancer tissue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits